Decreased expression of IL-17 pathway genes in blood in patients with plaque psoriasis treated with the anti-IL-17A monoclonal antibody, ixekizumab

被引：0
|
作者：
Krueger, J. G. [1 ]
Dow, E. R. [2 ]
Nantz, E. [2 ]
Komocsar, W. J. [2 ]
Banerjee, P. [2 ]
Leonardi, C. [3 ]
Cameron, G. S. [2 ]
Banerjee, S. [2 ]
Hoffman, R. W. [2 ]
机构：
[1] Rockefeller Univ, New York, NY 10021 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] St Louis Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2013年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
104
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] IXEKIZUMAB Anti-IL-17A monoclonal antibody Treatment of psoriasis
    Haddley, K.
    DRUGS OF THE FUTURE, 2015, 40 (07) : 421 - 431
  • [2] Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
    Blauvelt, Andrew
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 255 - 263
  • [3] Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis
    Toussirot, Eric
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (01) : 101 - 107
  • [4] Population Pharmacokinetics of Xeligekimab: An Anti-IL-17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
    Meng, Qingheng
    Wang, Wei
    Zhang, Lingxiao
    Shi, Haiyang
    Liu, Hongxia
    Zheng, Qingshan
    Xu, Ling
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (01): : 53 - 65
  • [5] Targeting IL-17 with ixekizumab in patients with psoriasis
    Dyring-Andersen, Beatrice
    Skov, Lone
    Zachariae, Claus
    IMMUNOTHERAPY, 2015, 7 (09) : 957 - 966
  • [6] Effectiveness of Ixekizumab in psoriasis patients previously treated with other IL-17 pathway inhibitors
    Chlinos, Antonios
    Beka, Panagiota
    Papoutsaki, Marina
    Panagakis, Panteleimon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB154 - AB154
  • [7] Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
    Hanley, Tessa L.
    Yiu, Zenas Z. N.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 315 - 323
  • [8] Challenges of systemic IL-17A quantification in patients treated with secukinumab, an anti-IL-17A antibody
    Calonder, C.
    Helbaj, R.
    Spindeldreher, S.
    Lloyd, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S22 - S22
  • [9] Anti IL-17 in psoriasis
    Ly, Karen
    Smith, Mary P.
    Thibodeaux, Quinn
    Reddy, Vidhatha
    Liao, Wilson
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (11) : 1185 - 1194
  • [10] Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB183 - AB183
12345